#long-acting injectables

Three antibodies combined into one protected monkeys against a simian version of HIV, opening the door for human trials.

Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.

A trial of long-acting cabotegravir given every eight weeks found that it yielded adequate drug levels and was well tolerated.

Cabotegravir and rilpivirine combo shows promise as well-tolerated and effective antiretroviral regimen in a trial.

The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.

Now that he’s on PRO-140, an experimental weekly injection, Sheen “is feeling fantastic.”

In an ongoing small trial, adding a biweekly infusion of ibalizumab has helped quite a few people on failing antiretroviral regimens.

The actor is still in the FDA trial of an injectable HIV med.

The global trial of 4,500 trans women and cis men who have sex with men will see whether cabotegravir prevents HIV as well as daily Truvada.

In a Phase III trial, participants responded well to the addition of biweekly injections of the cloned antibody ibalizumab.

The actor is part of an FDA study on the weekly injectable PRO 140.

A long-acting injectable HIV regimen dosed every four weeks is slated to advance to Phase III trials in late 2016.

A roundup of the major presentations on HIV science at the international conference held July 22 to 28 outlines many exciting developments.

The trial will test giving the treatment every four weeks, which has controlled HIV better than the eight-week dosing schedule.

The injectable antibody 3BNC117 suppressed HIV and delayed viral rebound for up to 19 weeks in people with the virus who stopped their meds.

CytoDyn’s monoclonal antibody PRO 140 injected once a week suppressed HIV in some people living with the virus for well over a year.